Childhood rhabdomyosarcoma is a rare type of cancer that forms in the soft tissues of children, commonly in muscles attached to bones. Despite its rarity, it's one of the most common soft tissue sarcomas in children. Research in this area focuses on understanding the genetic mutations driving its development and identifying more effective treatment strategies. Recent advancements in cancer research have led to targeted therapies that aim to inhibit specific molecular pathways involved in tumor growth. Additionally, immunotherapy approaches, harnessing the body's immune system to target cancer cells, show promise in treating childhood rhabdomyosarcoma. Collaborative efforts among researchers worldwide continue to push the boundaries in improving outcomes for children battling this aggressive cancer.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China